Mitchell Sinkler & Starr PA raised its position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 25.5% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,091 shares of the company’s stock after purchasing an additional 629 shares during the period. Mitchell Sinkler & Starr PA’s holdings in Zoetis were worth $554,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also bought and sold shares of the company. Focus Financial Network Inc. ADV bought a new position in shares of Zoetis in the 4th quarter worth $2,159,000. Price T Rowe Associates Inc. MD raised its position in shares of Zoetis by 31.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock worth $2,707,262,000 after acquiring an additional 3,244,074 shares in the last quarter. Axiom Investors LLC DE raised its position in shares of Zoetis by 36.3% in the 4th quarter. Axiom Investors LLC DE now owns 594,474 shares of the company’s stock worth $117,331,000 after acquiring an additional 158,459 shares in the last quarter. Global Assets Advisory LLC bought a new position in shares of Zoetis in the 1st quarter worth $8,831,000. Finally, Franklin Street Advisors Inc. NC raised its position in shares of Zoetis by 4.3% in the 1st quarter. Franklin Street Advisors Inc. NC now owns 121,024 shares of the company’s stock worth $20,478,000 after acquiring an additional 5,035 shares in the last quarter. 92.80% of the stock is owned by institutional investors.
Zoetis Stock Down 0.2 %
Zoetis stock opened at $191.37 on Wednesday. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. The business’s 50-day simple moving average is $181.93 and its two-hundred day simple moving average is $174.31. The company has a market cap of $86.70 billion, a PE ratio of 36.87, a PEG ratio of 2.90 and a beta of 0.88. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92.
Wall Street Analysts Forecast Growth
Several research analysts have recently commented on ZTS shares. BTIG Research boosted their price target on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Argus raised Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Piper Sandler upped their target price on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $200.00 target price on shares of Zoetis in a research report on Tuesday, August 27th. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $217.11.
Read Our Latest Analysis on Zoetis
Zoetis Company Profile
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
See Also
- Five stocks we like better than Zoetis
- Canadian Penny Stocks: Can They Make You Rich?
- Unlock Private Equity Opportunities for All Investors
- The Role Economic Reports Play in a Successful Investment Strategy
- Is Redfin Stock a Buy? Housing Market Recovery Could Fuel Upside
- Bank Stocks – Best Bank Stocks to Invest In
- An EV OEM Shakeout Is Underway: Who Will Win?
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.